Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention | Zendy

Neal Sawlani | Zendy; Robert A. Harrington | Zendy; Gregg W. Stone | Zendy; Philippe Gabríel Steg | Zendy; C. Michael Gibson | Zendy; Christian W. Hamm | Zendy; Matthew J. Price | Zendy; Jayne Prats | Zendy; Efthymios Deliargyris | Zendy; Kenneth W. Mahaffey | Zendy; Harvey D. White | Zendy; Deepak L. Bhatt | Zendy

Open Access

Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention

Author(s) -

Neal Sawlani,

Robert A. Harrington,

Gregg W. Stone,

Philippe Gabríel Steg,

C. Michael Gibson,

Christian W. Hamm,

Matthew J. Price,

Jayne Prats,

Efthymios Deliargyris,

Kenneth W. Mahaffey,

Harvey D. White,

Deepak L. Bhatt

Publication year - 2016

Publication title -

circulation cardiovascular interventions

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.621

H-Index - 95

eISSN - 1941-7632

pISSN - 1941-7640

DOI - 10.1161/circinterventions.116.004380

Subject(s) - cangrelor , medicine , percutaneous coronary intervention , clopidogrel , conventional pci , cardiology , p2y12 , randomized controlled trial , clinical endpoint , stroke (engine) , myocardial infarction , anesthesia , mechanical engineering , engineering

Cangrelor is a potent intravenous adenosine diphosphate-receptor antagonist that in the CHAMPION trials reduced the 48-hour and 30-day rates of ischemic events during percutaneous coronary intervention without an increase in severe bleeding.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research